Gerresheimer is a profitable sustainable growth company
The implementation of the formula g strategy process was again an important driver of Gerresheimer's growth in the financial year. With strong customer orientation, innovation and a focus on the highest quality, our company has again grown profitably – despite market headwinds.
Injectables dominate the global drug pipeline. Injectables are also the most widely used route of administration for biologics. They account for around 90% of the global drug pipeline. The biologics market is growing significantly faster than the overall market. We expect average annual growth of more than 15% in the submarkets in which we operate.
Our broad product portfolio enables us to address global megatrends and win orders for new innovative drugs, in particular biologics such as drugs based on the peptide hormone GLP-1 (glucagon-like peptide 1) for the treatment of obesity.
GLP-1 is an example of the large market potential for biologic drugs. This high market potential offers us the opportunity to continue to grow profitably in the future.



Further stories